Single-center experience of patients with interstitial lung diseases during the early days of te COVID-19 pandemic.
22 февраля 2021 года
05:45
Single-center experience of patients with interstitial lung diseases during the early days of te COVID-19 pandemic.
Текст новости:
Title: Single-center experience of patients with interstitial lung diseases during the early days of te COVID-19 pandemic.
Author, co-author: GUIOT, Julien; HENKET, Monique; Frix, Anne-Noëlle; GILTAY, Laurie; DENIS, Agnès; THYS, M; GESTER, Fanny; DELVAUX, M; MOUTSCHEN, Michel; CORHAY, Jean-Louis; LOUIS, Renaud; LAMBERMONT, Bernard; Covid-19 clinical investigators of the CHU de Liège
Abstract: Introduction: Patients with interstitial lung diseases (ILD) can be suspected to be at risk of experiencing a rapid flare-up due to COVID-19. However, no specific data are currently available for these patients.

Methods: We retrospectively analyzed a cohort of 401 patients with ILD and determined the proportion of patients hospitalized for proven severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and specific symptoms of COVID-19.

Results: We found that 1% of patients (n = 4) were hospitalized (1 in ICU) for COVID-19. In total, 310 of the 401 patients answered the phone call. Only 33 patients (0.08%) experienced specific symptoms of SARS-CoV-2 infection.

Conclusion: Our study did not demonstrate any increased occurrence of severe COVID-19 in ILD patients compared to the global population. Based on our findings, we could not make any conclusion on the incidence rate of SARS-CoV-2 infection in patients with ILDs, or on the overall outcome of immunocompromised patients affected by COVID-19.


Текст со страницы (автоматическое получение):
Single-center experience of patients with interstitial lung diseases during the early days of te COVID-19 pandemic.
Abstract :
[en] Introduction: Patients with interstitial lung diseases (ILD) can be suspected to be at risk of experiencing a rapid flare-up due to COVID-19. However, no specific data are currently available for these patients.
Methods: We retrospectively analyzed a cohort of 401 patients with ILD and determined the proportion of patients hospitalized for proven severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and specific symptoms of COVID-19.
Results: We found that 1% of patients (n = 4) were hospitalized (1 in ICU) for COVID-19. In total, 310 of the 401 patients answered the phone call. Only 33 patients (0.08%) experienced specific symptoms of SARS-CoV-2 infection.
Conclusion: Our study did not demonstrate any increased occurrence of severe COVID-19 in ILD patients compared to the global population. Based on our findings, we could not make any conclusion on the incidence rate of SARS-CoV-2 infection in patients with ILDs, or on the overall outcome of immunocompromised patients affected by COVID-19.
Permalink :
Автоматическая система мониторинга и отбора информации
Источник
Другие материалы рубрики
★★  21 февраля 2021 года
05:46
Proceedings of the 7th FARAH-Day
★★  21 февраля 2021 года
05:46
Proceedings of the 6th FARAH-Day
★★  20 февраля 2021 года
21:47
Anthropogenic particles in sediment from an Arctic fjord
  19 февраля 2021 года
23:15
От чего умирают больные Covid-19